No Data
Selling ATU's USA and United Kingdom Business, the strategy behind WUXI APPTEC.
There is gain in loss.
WUXI APPTEC will transfer the WuXi ATU Business to a USA Fund. Is the "optimal solution" for the "gray rhino" of the Biological Safety Act?
① This evening, WUXI APPTEC announced that it will transfer its WuXi ATU Business in the USA and United Kingdom to the USA Private Equity Fund Altaris in exchange for Cash.; ② In the first three quarters, WuXi ATU achieved revenue of 0.853 billion, accounting for only about 3% of the total revenue for the first three quarters.; ③ After the transfer of this Business, the accusations and suspicions related to its gene business may be cleared under the Biosecurity Act.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
Valued at 2 billion dollars! HANSOH PHARMA grants Merck exclusive global licensing rights for the oral weight loss drug.
① Merck and HANSOH PHARMA in China signed a $2 billion agreement to develop and sell the experimental oral weight loss drug HS-10535, which has effects similar to Wegovy and Zepbound; ② HANSOH PHARMA granted Merck global exclusive licensing rights for HS-10535, receiving an initial payment of $0.112 billion and up to $1.9 billion in milestone payments, along with royalties based on product sales.
Merck, Hansoh Pharma Enter Exclusive Global License Agreement For HS-10535, An Investigational Preclinical Oral Small Molecule GLP-1 Receptor Agonist; Hansoh To Receive An Upfront Payment Of $112M And Up To $1.9B In Milestones